Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Chardan Capital analyst Keay Nakae downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:MCRB) from Buy to Neutral but raised the price target from $1.25 to $6. Seres Therapeutics shares closed at $8.29 on Wednesday. See how other analysts view …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Chardan Capital analyst Keay Nakae downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:MCRB) from Buy to Neutral but raised the price target from $1.25 to $6. Seres Therapeutics shares closed at $8.29 on Wednesday. See how other analysts view …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Chardan Capital analyst Keay Nakae downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:MCRB) from Buy to Neutral but raised the price target from $1.25 to $6. Seres Therapeutics shares closed at $8.29 on Wednesday. See how other analysts view …Full story available on Benzinga.com Read MoreAXTA, COTY, MCRB, News, Top Downgrades, TOVX, Downgrades, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, COTY, AXTA, MCRB, TOVX, News, Downgrades, Price Target, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
